Amundi reduced its holdings in Moderna, Inc. (NASDAQ:MRNA) by 20.9% during the first quarter, selling 238,790 shares to retain a position valued at approximately $45.96 million. While Amundi decreased its stake, other institutional investors like MUFG Securities EMEA and Flagship Harbor Advisors established new positions,...
Moderna (MRNA) shares surged to a 52-week peak of $81.42 on July 6, marking a 169% annual gain and pushing the market cap to approximately $32.2 billion. This rally was driven by renewed enthusiasm for mRNA technology, including FDA advisory panel endorsement for its seasonal...
Simply Wall St analyzes Moderna (MRNA), noting a recent surge with a 51.4% year-to-date return and a current price of $46.71. The article questions whether the market has overvalued the stock, citing a DCF model that projects significant future cash outflows until 2030, resulting in...
Moderna (MRNA) shares rose 4.6% following a post-earnings repricing driven by stronger international vaccine deliveries and reiterated growth frameworks for 2026. The company reported first-quarter 2026 revenue of $389 million, with approximately 80% derived from international markets under long-term partnership agreements. Management highlighted a plan...
BioNTech is generating significant headlines with dual momentum in its oncology pipeline and an escalating legal strategy against competitors. At the AACR Annual Meeting 2026, the company presented updated Phase 1 data for its personalized mRNA cancer vaccine, Autogene Cevumeran (BNT122), developed in collaboration with...
